Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Given Average Rating of “Moderate Buy” by Analysts

Shares of Swedish Orphan Biovitrum (OTCMKTS:BIOVF) have earned a consensus recommendation of “Moderate Buy” from the seven brokerages that are covering the firm, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company.

A number of analysts have commented on BIOVF shares. Zacks Research upgraded shares of Swedish Orphan Biovitrum to a “hold” rating in a research note on Thursday, May 7th. Pareto Securities lowered shares of Swedish Orphan Biovitrum to a “hold” rating in a research note on Monday, June 29th. HC Wainwright began coverage on shares of Swedish Orphan Biovitrum in a report on Wednesday, May 6th. They issued a “buy” rating on the stock. Barclays reiterated an “overweight” rating on shares of Swedish Orphan Biovitrum in a research note on Friday, July 3rd. Finally, Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Swedish Orphan Biovitrum in a research report on Tuesday, July 21st.

Swedish Orphan Biovitrum Stock Performance

Shares of Swedish Orphan Biovitrum stock opened at $48.20 on Thursday. The stock has a market cap of $17.16 billion, a P/E ratio of 107.12 and a beta of 0.35. The company has a quick ratio of 0.47, a current ratio of 0.70 and a debt-to-equity ratio of 0.19. Swedish Orphan Biovitrum has a 12-month low of $28.93 and a 12-month high of $49.03. The business’s 50 day moving average is $48.17 and its 200-day moving average is $42.95.

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) last released its earnings results on Tuesday, April 28th. The company reported $0.45 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.07. Swedish Orphan Biovitrum had a net margin of 4.74% and a return on equity of 18.27%. The business had revenue of $755.76 million during the quarter, compared to analysts’ expectations of $749.76 million. Equities research analysts predict that Swedish Orphan Biovitrum will post 1.94 earnings per share for the current fiscal year.

About Swedish Orphan Biovitrum

Swedish Orphan Biovitrum AB (publ), commonly known as Sobi, is a Stockholm‐based biopharmaceutical company specializing in the development, manufacturing and commercialization of treatments for rare diseases. Formed in 2010 through the merger of Swedish Orphan International AB (established 1985) and Biovitrum AB, the company focuses on high‐value therapies in hematology, immunology, oncology and genetic/metabolic disorders. Sobi’s strategy centers on building a global specialty care portfolio by in‐licensing, acquiring and internally developing innovative products aimed at small patient populations with significant unmet needs.

The company’s marketed portfolio includes recombinant clotting factor therapies such as Elocta (rFVIIIFc) and Alprolix (rFIXFc) for hemophilia A and B, respectively; Ruconest, a recombinant human C1 esterase inhibitor for hereditary angioedema; and Kineret (anakinra) for certain auto‐inflammatory conditions.